CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Adefovir Dipivoxil for oral suspension, 2 mg/mLdrug
Likely dose
Adefovir Dipivoxil for oral suspension, 2 mg/mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00071201
NCT00071201Phase 3Completed
CompareCT.gov

A Multi-Center Phase 3, Open-Label, Parallel-Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B and Varying Degrees of Renal Impairment

Gilead Sciences·interventional·Posted Oct 17, 2003·Updated Oct 16, 2013

In Brief

A Phase 3 clinical trial evaluating Adefovir Dipivoxil for oral suspension, 2 mg/mL for Chronic Hepatitis B. Completed, across 1 site.

Detailed Summary

This is a multi-center phase 3, open-label, parallel-group study designed to evaluate the efficacy, safety and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and varying degrees of renal impairment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis B
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 17, 2003
Enrollment StartJun 1, 2003
Primary CompletionMar 1, 2006
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 22.7 years ago

Interventions

Adefovir Dipivoxil for oral suspension, 2 mg/mLdrug